Top in endocrinology: Cannabis and diabetic ketoacidosis, Medicare coverage of CGMs
Click Here to Manage Email Alerts
A recent study suggests that cannabis use may cause symptoms similar to diabetic ketoacidosis in patients with type 1 diabetes. A review of the data was the top story in endocrinology last week.
The second top story was about a final CMS rule that will expand Medicare coverage of continuous glucose monitors.
Read these and more in endocrinology below:
Cannabis use may cause DKA-like symptoms in type 1 diabetes
Patients with type 1 diabetes presenting with symptoms of diabetic ketoacidosis may instead have ketosis due to cannabis hyperemesis syndrome, and several criteria can help avoid a misdiagnosis, according to data published in Diabetes Care. Read more.
CMS expands Medicare coverage for all CGMs
CMS will expand Medicare coverage for all types of continuous glucose monitors, including adjunctive and non-adjunctive CGMs. The final rule, issued Dec. 21, classifies adjunctive CGMs under the Medicare Part B benefit for durable medical equipment (DME) and finalizes certain DME payment provisions that were included in two interim final rules. Read more.
New drugs bring dual benefits for ‘intertwined’ diabetic kidney disease, CVD
Diabetic kidney disease is the leading cause of end-stage renal disease in the U.S., and 50% of adults initiating renal replacement therapy have diabetes, according to the CDC. Read more.
FDA approves second insulin glargine biosimilar
The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic response in children and adults with type 1 diabetes and adults with type 2 diabetes. Read more.
Nearly one-third of adults prescribed hybrid closed-loop system do not initiate auto mode
About 31% of a group of adults with type 1 diabetes prescribed a hybrid closed-loop insulin delivery system never initiated auto mode, and half of the never initiated group consisted of Black and Hispanic patients, according to study data. Read more.